Dashboard
1
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 0.78%
- Poor long term growth as Operating profit has grown by an annual rate 18.76% of over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
2
With ROE of 0.95%, it has a Expensive valuation with a 2.12 Price to Book Value
3
Underperformed the market in the last 1 year
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-15.32%
0%
-15.32%
6 Months
-5.24%
0%
-5.24%
1 Year
13.71%
0%
13.71%
2 Years
8.74%
0%
8.74%
3 Years
-11.56%
0%
-11.56%
4 Years
-52.05%
0%
-52.05%
5 Years
-53.18%
0%
-53.18%
TOT BIOPHARM International Co. Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
133.77%
EBIT Growth (5y)
18.76%
EBIT to Interest (avg)
-59.45
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0.53
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0.45%
ROE (avg)
0.78%
Valuation key factors
Factor
Value
P/E Ratio
224
Industry P/E
Price to Book Value
2.12
EV to EBIT
-493.33
EV to EBITDA
22.62
EV to Capital Employed
2.10
EV to Sales
1.49
PEG Ratio
0.80
Dividend Yield
NA
ROCE (Latest)
-0.43%
ROE (Latest)
0.95%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'23
Dec'23
Dec'22
Change(%)
Net Sales
862.60
514.20
67.76%
Operating Profit (PBDIT) excl Other Income
-56.00
-11.70
-378.63%
Interest
5.70
7.70
-25.97%
Exceptional Items
0.00
1.10
-100.00%
Consolidate Net Profit
-41.70
-58.20
28.35%
Operating Profit Margin (Excl OI)
-65.00%
-107.90%
4.29%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2023 is 67.76% vs 458.91% in Dec 2022
Consolidated Net Profit
YoY Growth in year ended Dec 2023 is 28.35% vs 81.51% in Dec 2022
About TOT BIOPHARM International Co. Ltd. 
TOT BIOPHARM International Co. Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






